Account
Inquiry
Amble Tirzepatide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonist. This innovative compound represents a significant advancement in metabolic research, particularly for type 2 diabetes studies.
The molecular structure of Amble Tirzepatide features a unique combination of GLP-1 and GIP receptor agonism in a single molecule. This dual mechanism offers researchers a valuable tool for investigating metabolic pathways and potential therapeutic applications.
In research settings, Amble Tirzepatide has demonstrated promising effects on glucose metabolism and weight management. The compound works through multiple mechanisms including slowing gastric emptying, reducing hepatic glucose production, and enhancing pancreatic insulin secretion in response to elevated blood glucose levels.
For laboratory use, Amble Tirzepatide is supplied as a white lyophilized powder with high stability when stored properly. The compound maintains its integrity when stored at recommended temperatures, making it suitable for various research protocols.
Researchers have noted that Amble Tirzepatide may offer advantages in studies investigating metabolic syndrome, obesity-related conditions, and diabetes management. Its dual receptor activity provides a unique pharmacological profile compared to single-receptor agonists.
This product is intended for research purposes only and not for human consumption. Proper laboratory safety protocols should always be followed when handling Amble Tirzepatide or any research compounds.
